Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN

SUPERNUS PHARMACEUTICALS

SUPERNUS PHARMACEUTICALS, INC.

SUPERNUS PHARMACEUTICALS clinical programs — 55 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
Status
Public
HQ
9715 Key West Ave, Rockville, Maryland 20850, US
Founded
2005
Employees
828
Programs
55
Drugs
25
Patents
68
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

SUPERNUS PHARMACEUTICALS projects

55 ClinicalTrials.gov programs sponsored by SUPERNUS PHARMACEUTICALS.

SUPERNUS PHARMACEUTICALS has 55 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

55 programs

Clinical programs

Page 1 of 2

  1. Brexanolone

    SUPERNUS PHARMACEUTICALS, INC.

    Post Partum Depression

    phase 3 small molecule completed

    1 trial

  2. MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule completed

    2 trials

  3. MYOBLOC Low Dose

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule terminated

    1 trial

  4. Oxcarbazepine XR

    SUPERNUS PHARMACEUTICALS, INC.

    Partial Epilepsy

    phase 3 small molecule completed

    1 trial

  5. Phase 2; Low Dose MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule active

    1 trial

  6. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule terminated

    1 trial

  7. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    ADHD

    phase 3 small molecule completed

    5 trials

  8. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 3 small molecule completed

    2 trials

  9. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  10. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsies, Partial

    phase 3 small molecule completed

    1 trial

  11. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Super-refractory Status Epilepticus

    phase 3 small molecule completed

    2 trials

  12. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials

  13. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  14. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  15. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  16. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  17. 817P203

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    1 trial

  18. BIS-001ER

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Impaired Awareness Seizures

    phase 2 small molecule active

    1 trial

  19. Botulinum Toxin Type B (Myobloc)

    SUPERNUS PHARMACEUTICALS, INC.

    Drooling

    phase 2 mab completed

    1 trial

  20. Brexanolone

    SUPERNUS PHARMACEUTICALS, INC.

    Tinnitus

    phase 2 small molecule completed

    1 trial

  21. Gocovri (extended-release amantidine)

    SUPERNUS PHARMACEUTICALS, INC.

    Radiation Encephalopathy

    phase 2 small molecule active

    1 trial

  22. IR Viloxazine

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 2 small molecule completed

    1 trial

  23. IR-TPM (Topamax)

    SUPERNUS PHARMACEUTICALS, INC.

    Migraine

    phase 2 small molecule terminated

    1 trial

  24. Molindone

    SUPERNUS PHARMACEUTICALS, INC.

    Impulsive Aggression Comorbid With ADHD in Children

    phase 2 small molecule completed

    1 trial

  25. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  26. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  27. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Severe Postpartum Depression

    phase 2 small molecule completed

    1 trial

  28. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 2 small molecule completed

    1 trial

  29. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington Disease

    phase 2 small molecule completed

    2 trials

  30. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  31. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  32. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Mild Cognitive Impairment

    phase 2 small molecule completed

    1 trial

  33. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  34. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  35. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Impulsive Aggression Comorbid With ADHD

    phase 2 small molecule completed

    1 trial

  36. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  37. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    2 trials

  38. SPN-821 2400 mg

    SUPERNUS PHARMACEUTICALS, INC.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  39. TPM XR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

  40. BIS-001 ER

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy, Complex Partial

    phase 1 small molecule completed

    1 trial

  41. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Healthy Volunteer

    phase 1 small molecule completed

    3 trials

  42. SAGE-904

    SUPERNUS PHARMACEUTICALS, INC.

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  43. SPN-804O

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsies, Partial

    phase 1 small molecule completed

    1 trial

  44. SPN-810M

    SUPERNUS PHARMACEUTICALS, INC.

    Impulsive Aggression Comorbid With ADHD

    phase 1 small molecule completed

    1 trial

  45. SPN-817, Treatment B

    SUPERNUS PHARMACEUTICALS, INC.

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  46. Topiramate IR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  47. [14C]-NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  48. 100mg SPN-812

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does SUPERNUS PHARMACEUTICALS have?

55 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.